Published Paper Details:

Gastric cancer remains a major cause of cancer-related mortality worldwide, largely due to late diagnosis and the systemic toxicity of conventional chemotherapy. Oral anticancer therapy is often limited by poor bioavailability, short gastric residence time, narrow absorption windows, and drug instability in the intestinal environment. Gastroretentive drug delivery systems (GRDDS) offer an effective approach to overcome these limitations by prolonging gastric retention and enabling controlled, site-specific drug release. This review summarizes recent advances in gastroretentive drug delivery systems for cancer chemotherapy, with emphasis on gastric cancer treatment. Various GRDDS strategies, including floating, mucoadhesive, swelling, magnetic, and expandable systems, are discussed along with the role of polymers and nanocarrier-based formulations. Recent studies involving anticancer agents such as 5-fluorouracil, capecitabine, curcumin, and doxorubicin are highlighted. Overall, GRDDS show strong potential for improving the safety and efficacy of oral cancer chemotherapy.